What one share of Avalo Therapeutics holds
We are a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (“mAb”) is in a Phase 2 clinical trial for hidradenitis suppurativa (“HS”).
Avalo Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.19 |
|---|---|
| Cash and investments | $1.61 |
| Book value | $8.48 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$1,063 | $2.42 | −$684.81 | — | −$277.78 |
| 2023 | — | −$113.58 | $0.57 | −$111.04 | — | — |
| 2024 | $0.06 | −$20.91 | $0.00 | −$6.54 | — | $12.70 |
| 2025 | $0.00 | −$5.84 | — | — | — | $4.49 |
Common questions about Avalo Therapeutics
How much does one share of Avalo Therapeutics earn?
Over the last 12 months, Avalo Therapeutics lost $4.19 for each share.
Does Avalo Therapeutics pay a dividend?
Avalo Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Avalo Therapeutics’s book value per share?
Avalo Therapeutics’s book value is $8.48 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Avalo Therapeutics have?
Each share of Avalo Therapeutics has $1.61 of cash and investments, as of June 30, 2026.
Has Avalo Therapeutics bought back shares?
Avalo Therapeutics’s share count rose about 34094% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.